Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1

By T. Fifis, Anita Gamvrellis, B. Crimeen‐Irwin, G. Pietersz, Jie Li, P. Mottram, I. McKenzie, M. Plebanski. Journal of Immunology, 2004

655 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Control of Polymeric Nanoparticle Size to Improve Therapeutic Delivery (2015, methodology): “Antigen-conjugated polystyrene NPs with a diameter of 40 – 50 nm were injected intradermally and stimulated a higher level of antibody response compared to NPs larger than 100 nm [85].”
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment (2020, background): “Among them, solid core nano-beads conjugated with antigens with a diameter of 40–50 nm have achieved 2 to 10-fold stronger responses than other particles, producing high levels of IFN-γ and antibodies [106].”